Polycomb genes are associated with response to imatinib in chronic myeloid leukemia

AIM: Imatinib is a tyrosine kinase inhibitor that has revolutionized the treatment of chronic myeloid leukemia (CML). Despite its efficacy, about a third of patients discontinue the treatment due to therapy failure or intolerance. The rational identification of patients less likely to respond to ima...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Epigenomics
Main Authors: Crea, Francesco, Di Paolo, Antonello, Liu, Hui Hsuan, Polillo, Marialuisa, Clermont, Pier-Luc, Guerrini, Francesca, Ciabatti, Elena, Ricci, Federica, Baratè, Claudia, Fontanelli, Giulia, Barsotti, Sara, Morganti, Riccardo, Danesi, Romano, Wang, Yuzhuo, Petrini, Mario, Galimberti, Sara, Helgason, Cheryl D
Formato: Artigo
Idioma:Inglês
Publicado em: Future Medicine Ltd 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5551942/
https://ncbi.nlm.nih.gov/pubmed/26343356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/epi.15.35
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados